共 8 条
[1]
2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia[J] Dinesh Khanna;John D. Fitzgerald;Puja P. Khanna;Sangmee Bae;Manjit K. Singh;Tuhina Neogi;Michael H. Pillinger;Joan Merill;Susan Lee;Shraddha Prakash;Marian Kaldas;Maneesh Gogia;Fernando Perez‐Ruiz;Will Taylor;Frédéric Lioté;Hyon Choi;Jasvinder A. Singh;Nicola Dalbeth;Sanford Kaplan;Vandana Niyyar;Danielle Jones;Steven A. Yarows;
[2]
Gout therapeutics: new drugs for an old disease[J] Christopher M Burns;Robert L Wortmann The Lancet 2011,
[3]
Placebo-Controlled; Double-Blind Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia Including Those With Gout in Japan: Phase 3 Clinical Study[J] Kamatani Naoyuki;Fujimori Shin;Hada Toshikazu;Hosoya Tatsuo;Kohri Kenjiro;Nakamura Toshitaka;Ueda Takanori;Yamamoto Tetsuya;Yamanaka Hisashi;Matsuzawa Yuji Journal of Clinical Rheumatology 2011,
[4]
An Allopurinol-Controlled; Randomized; Double-Dummy; Double-Blind; Parallel Between-Group; Comparative Study of Febuxostat (TMX-67); a Non-Purine-Selective Inhibitor of Xanthine Oxidase; in Patients With Hyperuricemia Including Those With Gout in Japan: Phase 3 Clinical Study[J] Naoyuki Kamatani;Shin Fujimori;Toshikazu Hada;Tatsuo Hosoya;Kenjiro Kohri;Toshitaka Nakamura;Takanori Ueda;Tetsuya Yamamoto;Hisashi Yamanaka;Yuji Matsuzawa Journal of Clinical Rheumatology 2011,
[5]
Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout[J] Michael E. Ernst;Michelle A. Fravel Clinical Therapeutics 2009,
[6]
A critical reappraisal of allopurinol dosing; safety; and efficacy for hyperuricemia in gout[J] Jeannie Chao;Robert Terkeltaub Current Rheumatology Reports 2009,
[7]
Pharmacokinetics and Pharmacodynamics of Febuxostat (TMX-67); a Non-Purine Selective Inhibitor of Xanthine Oxidase/Xanthine Dehydrogenase (NPSIXO) in Patients with Gout and/or Hyperuricemia[J] K. Komoriya;S. Hoshide;K. Takeda;H. Kobayashi;J. Kubo;M. Tsuchimoto;T. Nakachi;H. Yamanaka;N. Kamatani Nucleosides; Nucleotides and Nucleic Acids 2004,
[8]
Selectivity of febuxostat; a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase[J] Yasuhiro Takano;Kumiko Hase-Aoki;Hideki Horiuchi;Lin Zhao;Yoshinori Kasahara;Shiro Kondo;Michael A. Becker Life Sciences 2004,